Abstract
Objectives
To assess the inhibitory effect of gadoxetate disodium on the transporter system using indocyanine green (ICG).
Materials and Methods
Groups of six female B6 Albino mice were injected with the test agent (0.62 mmol/kg gadoxetate disodium) or phosphate-buffered saline (control) 10 min before injection of ICG. Identical fluorescence images were subsequently obtained to create time-efficiency curves of liver parenchymal uptake. The study was performed on hypothermic and normothermic mice. The logarithms of the absorption rate constants (logKa values) and of the elimination rate constants (logKe values) were calculated for each experimental condition, and between-group differences were compared using Student’s t-test.
Results
The logKe values of the test group were lower than those of the control group at both temperatures (-6.52 vs. -5.87 under hypothermic conditions and -4.54 vs. -4.14 under normothermic conditions), and both differences were statistically significant (p = 0.037, 0.015 respectively). In terms of the logKa values, although the difference did not reach statistical significance (p = 0.052), the test group had lower values than the control group under hypothermic conditions (-0.771 vs. -0.376). In normothermic mice, the logKa values for the test and control groups were 0.037 and 0.277 respectively, thus not significantly different (p = 0.404).
Conclusions
Gadoxetate disodium inhibited ICG excretion. Thus, gadoxetate disodium inhibited the ATP-binding cassette sub-family C member 2 transporter.
Key Points
• Gadoxetate disodium inhibited ICG excretion.
• Gadoxetate disodium tended to inhibit hepatic ICG uptake.
• Drug-drug interactions of gadoxetate disodium need further investigation.
Similar content being viewed by others
Abbreviations
- ABCC:
-
ATP-binding cassette sub-family C member
- FLI:
-
Fluorescence imaging
- ICG:
-
Indocyanine green
- MRI:
-
Magnetic resonance imaging
- MRP:
-
Multidrug resistance-associated protein
- NTCP:
-
Na+/taurocholate transport protein
- OATP:
-
Organic anion-transporting polypeptide
- PBS:
-
Phosphate-buffered saline
- ROI:
-
Region of interest
References
Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H (1991) A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 22:233–237
Hamm B, Staks T, Mühler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792
Vogl TJ, Kümmel S, Hammerstingl R et al (1996) Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200:59–67
Huppertz A, Balzer T, Blakeborough A et al (2004) Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 230:266–275
Motosugi U, Ichikawa T, Sou H et al (2009) Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 30:1042–1046
Tajima T, Takao H, Akai H et al (2010) Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 34:362–366
Giraudeau C, Leporq B, Doblas S et al (2017) Gadoxetate-enhanced MR imaging and compartmental modelling to assess hepatocyte bidirectional transport function in rats with advanced liver fibrosis. Eur Radiol 27:1804–1811
Joo I, Lee JM (2016) Recent advances in the imaging diagnosis of hepatocellular carcinoma: value of gadoxetic acid-enhanced MRI. Liver Cancer 5:67–87
Akai H, Kiryu S, Ohta Y et al (2017) The natural history of streptozotocin-stimulated non-alcoholic steatohepatitis mice followed by Gd-EOB-DTPA-enhanced MRI: Comparison with simple steatosis mice. Magn Reson Imaging 38:123–128
Kim YY, An C, Kim S, Kim MJ (2017) Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI. Eur Radiol. https://doi.org/10.1007/s00330-017-5188-y
van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE (1999) Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 290:153–157
Kato N, Yokawa T, Tamura A, Heshiki A, Ebert W, Weinmann HJ (2002) Gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats. Investig Radiol 37:680–684
Akai H, Yasaka K, Nojima M, Inoue Y, Ohtomo K, Kiryu S (2017) Influence of indocyanine green on hepatic Gd-EOB-DTPA uptake: a proof-of-concept study in mice. Investig Radiol 52:441–445
Chen WR, Adams RL, Higgins AK, Bartels KE, Nordquist RE (1996) Photothermal effects on murine mammary tumors using indocyanine green and an 808-nm diode laser: an in vivo efficacy study. Cancer Lett 98:169–173
Shirata C, Kaneko J, Inagaki Y et al (2017) Near-infrared photothermal/photodynamic therapy with indocyanine green induces apoptosis of hepatocellular carcinoma cells through oxidative stress. Sci Rep 7:13958
Fox IJ, Brooker LG, Heseltine DW, Essex HE, Wood EH (1957) A tricarbocyanine dye for continuous recording of dilution curves in whole blood independent of variations in blood oxygen saturation. Proc Staff Meet Mayo Clin 32:478–484
Cherrick GR, Stein SW, Leevy CM, Davidson CS (1960) Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest 39:592–600
Kitai T, Inomoto T, Miwa M, Shikayama T (2005) Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer 12:211–215
Tajima Y, Yamazaki K, Masuda Y et al (2009) Sentinel node mapping guided by indocyanine green fluorescence imaging in gastric cancer. Ann Surg 249:58–62
Ishizawa T, Fukushima N, Shibahara J et al (2009) Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer 115:2491–2504
Leonhardt M, Keiser M, Oswald S et al (2010) Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 38:1024–1028
de Graaf W, Häusler S, Heger M et al (2011) Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol 54:738–745
Muhler A, Oude Elferink RP, Weinmann HJ (1993) Complete elimination of the hepatobiliary mr contrast agent Gd-EOB-DTPA in hepatic dysfunction: An experimental study using transport-deficient, mutant rats. MAGMA 1:134–139
Huang L, Vore M (2001) Multidrug resistance p-glycoprotein 2 is essential for the biliary excretion of indocyanine green. Drug Metab Dispos 29:634–637
Kiryu S, Inoue Y, Watanabe M, Ohtomo K (2011) Effect of isoflurane anesthesia and hypothermia on the hepatic kinetics of Gd-EOB-DTPA: evaluation using MRI of conscious mice. J Magn Reson Imaging 34:354–360
Food and Drug Administration. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. July 06, 2005. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf. Accessed 1 Sept 2015.
Robert P, Lehericy S, Grand S et al (2015) T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Investig Radiol 50:473–480
Robert P, Violas X, Grand S et al (2016) Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Investig Radiol 51:73–82
Bussi S, Penard L, Bonafè R et al (2018) Non-clinical assessment of safety and gadolinium deposition after cumulative administration of gadobenate dimeglumine (MultiHance®) to neonatal and juvenile rats. Regul Toxicol Pharmacol 92:268–277
Motosugi U, Ichikawa T, Sano K et al (2011) Double-dose gadoxetic Acid-enhanced magnetic resonance imaging in patients with chronic liver disease. Investig Radiol 46:141–145
Kinner S, Steinweg V, Maderwald S et al (2014) Bile duct evaluation of potential living liver donors with Gd-EOB-DTPA enhanced MR cholangiography: Single-dose, double dose or half-dose contrast enhanced imaging. Eur J Radiol 83:763–767
Wang F, Nojima M, Inoue Y, Ohtomo K, Kiryu S (2015) Assessment of MRI contrast agent kinetics via retro-orbital injection in mice: comparison with tail vein injection. PLoS One 10:e0129326
Millard SP, Krause A (eds) (2001) Applied Statistics in the Pharmaceutical Industry: With Case Studies Using S-Plus. Springer, New York
Jia J, Puls D, Oswald S et al (2014) Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. Investig Radiol 49:78–86
Kiryu S, Inoue Y, Watanabe M et al (2009) Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine. Magn Reson Imaging 27:101–107
Segers J, Le Duc G, Laumonier C, Troprès I, Elst LV, Muller RN (2005) Evaluation of Gd-EOB-DTPA uptake in a perfused and isolated mouse liver model: correlation between magnetic resonance imaging and monochromatic quantitative computed tomography. Investig Radiol 40:574–582
Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693–705
Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y (1997) Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos 25:1123–1129
Vlaming ML, Pala Z, van Esch A et al (2008) Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin Cancer Res 14:8152–8160
Funding
This study has received funding by Japan Society for the Promotion of Science (JP16K10308).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Dr. Shigeru Kiryu.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
One of the authors (Dr. Masanori Nojima) is Master of Public Health and has significant statistical expertise.
Informed consent
Written informed consent was not required for this study because it is an experimental study using mice.
Ethical approval
Approval from the institutional animal care committee was obtained.
Methodology
• experimental
• performed at one institution
Rights and permissions
About this article
Cite this article
Akai, H., Yasaka, K., Kunimatsu, A. et al. The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green. Eur Radiol 28, 4128–4133 (2018). https://doi.org/10.1007/s00330-018-5403-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-018-5403-5